AI Slashes Drug Development Costs by 70% But Faces Scrutiny as No AI-Discovered Drug Has Yet Won FDA Approval

AI is slashing drug development costs by up to 70% and driving a projected $1 billion surge in new biopharma spending, but critics warn that no AI-discovered drug has yet received FDA approval, and the industry's notorious 90% failure rate may persist if human biological variability isn't properly addressed before clinical trials.

• AI is dramatically accelerating drug development, compressing preclinical costs and timelines by as much as 70%, according to a TD Cowen survey of 80 biopharma leaders.
• Demand for advanced simulation software, sequencing tools, and computational models is surging, with new drug development programs projected to grow more than 10% in three to five years and generate an additional $1 billion in incremental spending.
• Despite the rapid AI adoption, skeptics warn that no AI-discovered drug has yet received FDA approval, and the new drug failure rate could remain near 90% if human biological variability is not adequately accounted for before clinical trials.